Thursday, September 21, 2023 11:24:32 AM
RadioGel™ - FDA IDE Progress Update
We've received numerous emails regarding where we are on our timeline in regards to our FDA IDE submission progress with RadioGel™ .
We have chosen to respond to the main inquiries in a question-and-answer format, which will allow us to disseminate the information to our entire shareholder base, and not one particular shareholder or potential investor. Please note that we will not respond individually to any email that requests confidential information that has not been properly vetted and disclosed to the public.
Retail investor questions and answers:
When is the next FDA meeting or has Vivos already had it?
The next FDA Pre-Sub meeting is scheduled for Friday, September 29, 2023.
What is the status of the genotoxicity proposal - is it ready?
Per the FDA recommendation, the proposed Genotoxicity Chemical Characterization Protocol was sent to the FDA for their comments on 7/23/23. Unfortunately, it has taken this long to get on their schedule.
The FDA will give us written comments about a week before the meeting, which provides the basis for discussion.
Are you planning on submitting the IDE after the genotoxicity (proposal/testing/protocol) testing is finished, or are you staying on the same path?
Our specific plan for the next IDE submission depends on the results of the feedback from the FDA at the next meeting scheduled for September 29, 2023.
Collectively we decided that our approach would be to submit an amendment to the previous IDE. Listing and then addressing all the FDA comments over the last five years, and then providing the answers - sometimes for the second time. This allows us to build on our progress and is the optimum way to communicate since 50% of the FDA reviewers are new.
Thank you for your continued support.
Mike Korenko, Sc. D
CEO & President Vivos Inc.
Recent RDGL News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 06:28:50 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 09:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:40:48 PM
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 12/07/2023 05:15:10 AM
- Form 1-A POS - • Edgar (US Regulatory) • 11/27/2023 10:29:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2023 04:28:46 PM
- Form 1-A POS - • Edgar (US Regulatory) • 11/03/2023 09:03:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/19/2023 04:18:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 10:33:58 AM
- Form 1-A POS - • Edgar (US Regulatory) • 10/10/2023 04:05:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/04/2023 07:22:21 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM